Phase 1 Lymphoma Trial, Recruiting NCT06528301 Sponsor: Umoja Biopharma Condition: Lymphoma
Back to Lymphoma

Phase 1 Lymphoma Trial, Recruiting

NCT06528301
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must be willing and able to sign a consent form agreeing to take part in the trial
  • You have been diagnosed with a type of blood cancer called large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment
  • Your cancer must be measurable by standard medical tests used for your specific type of blood cancer (confirm with trial site)
  • You must not have any serious ongoing illnesses or infections that are active or not being controlled
  • You must be well enough to carry out daily activities with little to no limitation, based on a standard health scale used by doctors (confirm with trial site)
  • Your heart, liver, kidneys, and other major organs must be working well enough as determined by the trial team
  • If you have previously received a treatment that targets a protein called CD19, you must have had a biopsy showing that your cancer still has CD19 on its cells after that treatment ended

Who may not be able to join:

  • Women who are currently pregnant or breastfeeding
  • People whose cancer has spread only to the brain or spinal cord
  • People who have previously received a bone marrow transplant from a donor, gene therapy, or certain types of cell-based therapies (some exceptions may apply — confirm with trial site)
  • People who have HIV, whether currently active or previously diagnosed
  • People with currently active hepatitis B or hepatitis C infection
  • People with conditions that weaken the immune system, unless it is well-controlled Type 1 diabetes or a thyroid condition
  • People with an ongoing brain or nervous system condition that would make it difficult to assess neurological health during the trial
  • People with uncontrolled chest pain (angina) or other serious active heart conditions
  • People who are currently taking part in another clinical trial that involves a treatment intervention

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jacob Garcia, MD, Umoja Biopharma

Phone: 425-873-8331

Australian sites

Royal North Shore Hospital, Saint Leonards, New South Wales
+61299264377
St. Vincent's Hospital Melbourne, Fitzroy, Victoria
+61 3 9231 3263

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Umoja Biopharma
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
1 March 2029

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Percentage of participants with common adverse events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov